Skip to main content
SpringerLink
Log in

Effect of metabolic syndrome and its components on prostate cancer risk: Meta-analysis

  • Short Review
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Background: Literature data examining the role of metabolic syndrome and its components in prostate cancer risk are limited and contradictory. Aim: We did a meta-analysis of studies that evaluated the association between metabolic syndrome, its components, and risk of prostate cancer. Subjects and methods: We conducted an electronic search for articles published through September 2012 without restrictions. Every included study was to report risk estimates with 95% confidence intervals for the association between metabolic syndrome and prostate cancer. Results: The final number of papers included in the meta-analysis was 14, all published in English, with 4728 prostate cancer cases. Metabolic syndrome was associated with a 12% increase in prostate cancer risk (p=0.231), that was lower in cohort studies (7 studies, RR=1.04, p=0.791) than other studies (RR=1.23, p=0.125). The association was significant in the 8 European studies (RR=1.30, p=0.034), but not in the 4 U.S. or 2 Asiatic studies. The risk estimates of prostate cancer for higher values of body mass index, dysglycemia or dyslipidemia (high triglycerides, low HDL-cholesterol) were not significant; on the contrary, hypertension and waist circumference >102 cm were associated with a significant 15% (p=0.035) and 56% (p=0.007) greater risk of prostate cancer, respectively. Conclusions: Metabolic syndrome is weakly and non significantly associated with prostate cancer risk, but associations vary with geography. Among single components of the syndrome, hypertension and higher waist circumference are significantly associated with increased risk of prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62: 10–29.

    Article  PubMed  Google Scholar 

  2. OECD. Health at a Glance 2011: OECD Indicators. Paris: OECD Publishing, 2011.

    Google Scholar 

  3. Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci 2006, 11: 1388–413.

    Article  PubMed  CAS  Google Scholar 

  4. Hsing AW, Devesa SS. Trends and patterns of prostate cancer: what do they suggest? Epidemiol Rev 2001, 23: 3–13.

    Article  PubMed  CAS  Google Scholar 

  5. Alberti KGMM, Eckel RH, Grundy SM, et al; International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120: 1640–5.

    Article  PubMed  CAS  Google Scholar 

  6. Hsing AW, Sakoda LC, Chua SC. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 2007, 86: s843–57.

    PubMed  Google Scholar 

  7. Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer. Diabetes Care 2012, 35: 2402–11.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 2004, 47: 1071–8.

    Article  PubMed  CAS  Google Scholar 

  9. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009, 151: W65–94.

    Article  PubMed  Google Scholar 

  10. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med 2002, 21: 1539–58.

    Article  PubMed  Google Scholar 

  11. Tobias A. Assessing the influence of a single study in the metaanalysis estimate. Stata Tech Bull 1999, 8: 15–7.

    Google Scholar 

  12. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315: 629–34.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  13. Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT. Metabolic syndrome and the risk of prostate cancer in Finnish men: A population-based study. Cancer Epidemiol Biomarkers Prev 2004, 13: 1646–50.

    PubMed  CAS  Google Scholar 

  14. Lund Håheim L, Wisløff TF, Holme I, Nafstad P. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol 2006, 164: 769–74.

    Article  PubMed  Google Scholar 

  15. Tande AJ, Platz EA, Folsom AR. The metabolic syndrome Is associated with reduced risk of prostate cancer. Am J Epidemiol 2006, 164: 1094–102.

    Article  PubMed  Google Scholar 

  16. Inoue M, Noda M, Kurahashi N, et al; Japan Public Health Center-based Prospective Study Group. Impact of metabolic factors on subsequent cancer risk: results from a large-scale population-based cohort study in Japan. Eur J Cancer Prev 2009, 18: 240–7.

    Article  PubMed  Google Scholar 

  17. Martin RM, Vatten L, Gunnell D, Romundstad P, Nilsen TI. Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway. Cancer Causes Control 2009, 20: 1181–92.

    Article  PubMed  Google Scholar 

  18. Wallner LP, Morgenstern H, McGree ME, et al. The effects of metabolic conditions on prostate cancer incidence over 15 years of follow-up: results from the Olmsted County Study. BJU Int 2010, 107: 929–35.

    Article  PubMed Central  PubMed  Google Scholar 

  19. Grundmark B, Garmo H, Loda M, Busch C, Holmberg L, Zethelius B. The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes. Cancer Epidemiol Biomarkers Prev 2010, 19: 2088–96.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Beebe-Dimmer JL, Dunn RL, Sarma AV, Montie JE, Cooney KA. Features of the metabolic syndrome and prostate cancer in African-American men. Cancer 2007, 109: 875–81.

    Article  PubMed  Google Scholar 

  21. Tuohimaa P, Tenkanen L, Syvälä H, et al. Interaction of factors related to the metabolic syndrome and vitamin D on risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2007, 16: 302–7.

    Article  PubMed  CAS  Google Scholar 

  22. Russo A, Autelitano M, Bisanti L. Metabolic syndrome and cancer risk. Eur J Cancer 2008, 44: 293–7.

    Article  PubMed  Google Scholar 

  23. Beebe-Dimmer JL, Nock NL, Neslund-Dudas C, et al. Racial differences in risk of prostate cancer associated with metabolic syndrome. Urology 2009, 74: 185–90.

    Article  PubMed Central  PubMed  Google Scholar 

  24. Pelucchi C, Serraino D, Negri E, et al. The metabolic syndrome and risk of prostate cancer in Italy. Ann Epidemiol 2011, 21: 835–41.

    Article  PubMed  Google Scholar 

  25. De Nunzio C, Freedland SJ, Miano R, et al. Metabolic syndrome Is associated with high grade Gleason score when prostate cancer is diagnosed on biopsy. Prostate 2011, 71: 1492–8.

    Google Scholar 

  26. Osaki Y, Taniguchi S-I, Tahara A, Okamoto M, Kishimoto T. Metabolic syndrome and incidence of liver and breast cancers in Japan. Cancer Epidemiol 2012, 36: 141–7.

    Article  PubMed  Google Scholar 

  27. Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, Calle EE. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol 2005, 161: 147–52.

    Article  PubMed  Google Scholar 

  28. Kasper JS, Giovannucci E. Meta-analysis of diabetes mellitus and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006, 15: 2056–62.

    Article  PubMed  Google Scholar 

  29. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008, 371: 569–78.

    Article  PubMed  Google Scholar 

  30. MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 2006, 17: 989–1003.

    Article  PubMed  Google Scholar 

  31. Wallström P, Bjartell A, Gullberg B, Olsson H, Wirfält E. A prospective Swedish study on body size, body composition, diabetes, and prostate cancer risk. Br J Cancer 2009, 100: 1799–805.

    Article  PubMed Central  PubMed  Google Scholar 

  32. Jackson MD, Walker SP, Simpson CM, et al. Body size and risk of prostate cancer in Jamaican men. Cancer Causes Control 2010, 21: 909–17.

    Article  PubMed  Google Scholar 

  33. De Nunzio C, Albisinni S, Freedland SJ, et al. Abdominal obesity as risk factor for prostate cancer diagnosis and high grade disease: A prospective multicenter Italian cohort study. Urol Oncol 2011 Sep 16 [Epub ahead of print]; doi: 10.1016/j.urolonc.2011.08.007

  34. Nemesure B, Wu SY, Hennis A, Leske MC; Prostate Cancer in a Black Population (PCBP) Study Group. Central adiposity and Prostate Cancer in a Black Population. Cancer Epidemiol Biomarkers Prev 2012, 21: 851–8.

    Article  PubMed  Google Scholar 

  35. Pischon T, Boeing H, Weikert S, et al. Body size and risk of prostate cancer in the European prospective investigation intocancer and nutrition. Cancer Epidemiol Biomarkers Prev 2008, 17: 3252–61.

    Article  PubMed  Google Scholar 

  36. Nomura AM. Body size and prostate cancer. Epidemiol Rev 2001, 23: 126–31.

    Article  PubMed  CAS  Google Scholar 

  37. Wolk A, Mantzoros CS, Andersson SO, et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998, 90: 911–5.

    Article  PubMed  CAS  Google Scholar 

  38. Moyad MA. Is obesity a risk factor for prostate cancer, and does it even matter? A hypothesis and different perspective. Urology 2002, 59(Suppl 1): 41–50.

    Article  PubMed  Google Scholar 

  39. Ulmer H, Borena W, Rapp K, et al. Serum triglyceride concentrations and cancer risk in a large cohort study in Austria. Br J Cancer 2009, 101: 1202–6.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  40. Van Hemelrijck M, Garmo H, Holmberg L, et al. Prostate cancer risk in the Swedish AMORIS study: the interplay among triglycerides, total cholesterol, and glucose. Cancer 2011, 117: 2086–95.

    Article  PubMed  CAS  Google Scholar 

  41. Martin RM, Vatten L, Gunnell D, Romundstad P, Nilsen TI. Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway. Cancer Causes Control 2009, 20: 1181–92.

    Article  PubMed  Google Scholar 

  42. Mondul AM, Weinstein SJ, Virtamo J, Albanes D. Serum total and HDL cholesterol and risk of prostate cancer. Cancer Causes Control 2011, 22: 1545–52.

    Article  PubMed Central  PubMed  Google Scholar 

  43. Kok DE, van Roermund JG, Aben KK, et al. Blood lipid levels and prostate cancer risk; a cohort study. Prostate Cancer Prostatic Dis 2011, 14: 340–5.

    Article  PubMed  CAS  Google Scholar 

  44. Jacobs EJ, Stevens VL, Newton CC, Gapstur SM. Plasma total, LDL, and HDL cholesterol and risk of aggressive prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Causes Control 2012, 23: 1289–96.

    Article  PubMed  Google Scholar 

  45. Jaggers JR, Sui X, Hooker SP, et al. Metabolic syndrome and risk of cancer mortality in men. Eur J Cancer 2009, 45: 1831–8.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  46. Morote J, Ropero J, Planas J, et al. Metabolic syndrome increases the risk of aggressive prostate cancer detection. BJU Int 2012, Aug 9 [Epub ahead of print]. doi: 10.1111/j.1464-410X.2012.11406.x.

  47. Kheterpal E, Sammon JD, Diaz M, et al. Effect of metabolic syndrome on pathologic features of prostate cancer. Urol Oncol 2012, Sep 25 [Epub ahead of print]; doi 10.1016/j.urolonc.2011.12.012

  48. Esposito K, Giugliano D. Obesity, the metabolic syndrome, and sexual dysfunction in men. Clin Pharmacol Ther 2011, 90: 169–73.

    Article  PubMed  CAS  Google Scholar 

  49. Corona G, Baldi E, Maggi M. Androgen regulation of prostate cancer: where are we now? J Endocrinol Invest 2011, 34: 232–43.

    Article  PubMed  CAS  Google Scholar 

  50. Jannini EA, Gravina GL, Mortengaler A, Morales A, Incocci L, Hellstrom WJG. Is testosterone a friend or a foe of the prostate? J Sex Med 2011, 8: 946–55.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardio-Thoracic and Respiratory Sciences, Second University of Naples, Naples, Italy

    K. Esposito MD, PhD & M. I. Maiorino

  2. Department of Medicine and Public Health, Second University of Naples, Naples, Italy

    P. Chiodini

  3. Department of Experimental Medicine, Second University of Naples, Naples, Italy

    A. Capuano & E. Parretta

  4. Department of Geriatrics and Metabolic Diseases, Second University of Naples, Naples, Italy

    G. Bellastella & D. Giugliano

  5. Department of Experimental Medicine, University of Rome “La Sapienza”, Rome, Italy

    A. Lenzi

Authors
  1. K. Esposito MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Chiodini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Capuano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Bellastella
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. I. Maiorino
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. Parretta
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Lenzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D. Giugliano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Esposito MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Esposito, K., Chiodini, P., Capuano, A. et al. Effect of metabolic syndrome and its components on prostate cancer risk: Meta-analysis. J Endocrinol Invest 36, 132–139 (2013). https://doi.org/10.1007/BF03346748

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03346748

Key-words

Search

Navigation